|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-12-17
|
|
pubmed:abstractText |
High-dose chemotherapy with autologous stem cell transplantation after initial cytoreductive chemotherapy with the combination vincristine, doxorubicin and dexamethasone (VAD) is considered an effective therapy for many patients with newly diagnosed, symptomatic multiple myeloma. Response to initial cytoreductive chemotherapy is important for the long-term outcome of such patients. Thalidomide has recently shown significant antimyeloma activity. We studied the efficacy and toxicity of the combination of a liposomal doxorubicin-containing VAD regimen with thalidomide, administered on an outpatient basis, as initial cytoreductive treatment in previously untreated patients with symptomatic myeloma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AnagnostopoulosAA,
pubmed-author:DimopoulosM AMA,
pubmed-author:Greek Myeloma Study Group,
pubmed-author:HatzicharissiEE,
pubmed-author:KorantzisJJ,
pubmed-author:ManiatisAA,
pubmed-author:MitsouliChCh,
pubmed-author:PanagiotidisPP,
pubmed-author:PapaioannouMM,
pubmed-author:TzilianosMM,
pubmed-author:ZervasKK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
134-8
|
|
pubmed:dateRevised |
2009-11-3
|
|
pubmed:meshHeading |
pubmed-meshheading:14679133-Adult,
pubmed-meshheading:14679133-Aged,
pubmed-meshheading:14679133-Ambulatory Care,
pubmed-meshheading:14679133-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14679133-Dexamethasone,
pubmed-meshheading:14679133-Doxorubicin,
pubmed-meshheading:14679133-Drug Administration Schedule,
pubmed-meshheading:14679133-Female,
pubmed-meshheading:14679133-Humans,
pubmed-meshheading:14679133-Injections, Intravenous,
pubmed-meshheading:14679133-Male,
pubmed-meshheading:14679133-Middle Aged,
pubmed-meshheading:14679133-Multiple Myeloma,
pubmed-meshheading:14679133-Stem Cell Transplantation,
pubmed-meshheading:14679133-Thalidomide,
pubmed-meshheading:14679133-Transplantation, Autologous,
pubmed-meshheading:14679133-Treatment Outcome,
pubmed-meshheading:14679133-Vincristine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
|
|
pubmed:affiliation |
Greek Myeloma Study Group, Athens, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
